ArticleSaudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
The efficacy and safety of biweekly valganciclovir 450 mg for prophylaxis of recurrent cytomegalovirus anterior uveitis.
Article in Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral anterior uveitis (AU) can be caused by a multitude of viruses, including cytomegalovirus (CMV). It can be a potentially vision-threatening condition. Thus, it requires prompt diagnosis and treatment as well as long-term prophylaxis to prevent the dire effects of recurrences. This case involved a 45-year-old Egyptian woman with a long history of unilateral recurrent AU that was polymerase chain reaction proven to be due to CMV. She was treated with oral valganciclovir and then placed on maintenance therapy. In this case, we shed the light on the possibility of reducing the prophylactic dose to a 450 mg biweekly dose of oral valganciclovir. Considering a lower dose of oral valganciclovir may help practitioners avoid the side effects of oral valganciclovir as well as reduce the overall financial burden in long-term prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.